Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Levodopa 100mg/5ml oral liquid
0409010I0AAAKAK
|
Levodopa | Levodopa | Central Nervous System | No data available |
|
Levodopa 125mg/5ml oral suspension
0409010I0AAAJAJ
|
Levodopa | Levodopa | Central Nervous System | No data available |
|
Levodopa 25mg/5ml oral suspension
0409010I0AAAMAM
|
Levodopa | Levodopa | Central Nervous System | No data available |
|
Levodopa 33mg inhalation powder capsules with device
0409010I0AAANAN
|
Levodopa | Levodopa | Central Nervous System | No data available |
|
Levodopa 500mg tablets
0409010I0AAAFAF
|
Levodopa | Levodopa | Central Nervous System | No data available |
|
Levofloxacin 100mg/ml nebuliser liquid ampoules
0501120X0AAAFAF
|
Levofloxacin | Levofloxacin | Infections | No data available |
|
Levofloxacin 500mg/100ml infusion bags
0501120X0AAADAD
|
Levofloxacin | Levofloxacin | Infections | No data available |
|
Levofloxacin 500mg/100ml infusion polyethylene bottles
0501120X0AAAGAG
|
Levofloxacin | Levofloxacin | Infections | No data available |
|
Levofloxacin 500mg/100ml solution for infusion bottles
0501120X0AAAEAE
|
Levofloxacin | Levofloxacin | Infections | No data available |
|
Levofloxacin 500mg/100ml solution for infusion vials
0501120X0AAACAC
|
Levofloxacin | Levofloxacin | Infections | No data available |
|
Levofolinic acid 200mg/4ml solution for injection vials
0801000Z0AAABAB
|
Levofolinic acid | Levofolinic acid | Malignant Disease and Immunosuppression | No data available |
|
Levofolinic acid 50mg/1ml solution for injection vials
0801000Z0AAAAAA
|
Levofolinic acid | Levofolinic acid | Malignant Disease and Immunosuppression | No data available |
|
Levomepromazine 10mg/5ml oral liquid
0402010K0AAAJAJ
|
Levomepromazine maleate | Levomepromazine maleate | Central Nervous System | No data available |
|
Levomepromazine 12.5mg/5ml oral liquid
0402010K0AAAEAE
|
Levomepromazine maleate | Levomepromazine maleate | Central Nervous System | No data available |
|
Levomepromazine 1mg capsules
0402010K0AAATAT
|
Levomepromazine maleate | Levomepromazine maleate | Central Nervous System | No data available |
|
Levomepromazine 25mg/5ml oral liquid
0402010K0AAAFAF
|
Levomepromazine maleate | Levomepromazine maleate | Central Nervous System | No data available |
|
Levomepromazine 3mg/5ml oral liquid
0402010K0AAAQAQ
|
Levomepromazine maleate | Levomepromazine maleate | Central Nervous System | No data available |
|
Levomepromazine 4mg/5ml oral liquid
0402010K0AAAKAK
|
Levomepromazine maleate | Levomepromazine maleate | Central Nervous System | No data available |
|
Levomepromazine 50mg/5ml oral liquid
0402010K0AAAHAH
|
Levomepromazine maleate | Levomepromazine maleate | Central Nervous System | No data available |
|
Levomepromazine 6.25mg/5ml oral liquid
0402010K0AAADAD
|
Levomepromazine maleate | Levomepromazine maleate | Central Nervous System | No data available |
|
Levomepromazine maleate 2.5mg/5ml oral solution
0402010K0AAALAL
|
Levomepromazine maleate | Levomepromazine maleate | Central Nervous System | No data available |
|
Levomepromazine maleate 6mg/5ml oral solution
0402010K0AAAPAP
|
Levomepromazine maleate | Levomepromazine maleate | Central Nervous System | No data available |
|
Levomilnacipran 40mg modified-release capsules
0403040AAAAAAAA
|
Levomilnacipran | Levomilnacipran | Central Nervous System | No data available |
|
Levomilnacipran 80mg modified-release capsules
0403040AAAAABAB
|
Levomilnacipran | Levomilnacipran | Central Nervous System | No data available |
|
Levonelle 750microgram tablets
0703050A0BCABAA
|
Levonelle | Levonorgestrel | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.